Additional Relevant Details
This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene's management and in accordance with the requirements of the Securities and Exchange Commission. Celgene now has a total of approximately $5.3 billion available from previous authorizations plus the new authorization. Since 2009, Celgene has returned approximately $15.2 billion to shareholders through the repurchase program.